Northwire Canada EditionWednesday, July 15, 2026
Northwire
EFF 0.030 +20.0% W 0.500 +1.0% RDG 0.160 +0.0% ARIC 0.780 +4.0% VROY 3.44 +5.2% ROCK 3.81 +3.0% APMI 0.120 +0.0% EM 3.58 −4.8% ALS 66.04 +6.8% MEK 0.065 +44.4% TLO 6.00 +13.0% ADE 0.045 −66.7% FAIR 0.060 +33.3% SVRS 0.420 −2.3% RES 0.050 +42.9% CYG 0.120 +0.0% EFF 0.030 +20.0% W 0.500 +1.0% RDG 0.160 +0.0% ARIC 0.780 +4.0% VROY 3.44 +5.2% ROCK 3.81 +3.0% APMI 0.120 +0.0% EM 3.58 −4.8% ALS 66.04 +6.8% MEK 0.065 +44.4% TLO 6.00 +13.0% ADE 0.045 −66.7% FAIR 0.060 +33.3% SVRS 0.420 −2.3% RES 0.050 +42.9% CYG 0.120 +0.0%
Other

MindBio Advances Large-Scale Deployment of Voice Intoxication Detection Through Integrated Edge AI Hardware-Software Platform

MBIO · Price

Executive Summary

  • MindBio Therapeutics announced the commencement of development for a proprietary Edge AI hardware platform to deliver real‑time, on‑device voice analysis for drug and alcohol intoxication detection in mining operations.
  • Prototype completion is near, with hardware manufacturing and field deployment slated for Q2 2026; the solution will be sold directly and through distributors, generating recurring software revenue.
  • The company has begun operations in South America, establishing testing protocols and engaging mining operators and health authorities in Chile to align with regulatory frameworks, positioning MindBio for large‑scale rollout in the mining sector and future expansion into other safety‑critical industries.

Key Details

  • Edge Computing Platform: Integrated Edge AI solution combining dedicated hardware and voice analytics software for on‑device intoxication detection.
  • Prototype Status: Near completion; manufacturing and field‑ready deployment expected in Q2 2026.
  • Revenue Model: One‑time device sale plus recurring subscription fees for the Voice AI intoxication detection models.
  • Target Market – Mining: Initial commercial focus on Chilean mining operators; collaboration with local health authorities to meet mandatory drug/alcohol testing regulations.
  • Geographic Expansion: Operations launched in South America with plans to scale across additional safety‑critical sectors (aviation, heavy industry).
  • Market Opportunity Data: In Chile, >75% of mining workers consume alcohol, 40% are problem drinkers, and ~9% report drug use; 20–25% of occupational accidents linked to substance use, underscoring demand for non‑invasive detection technology.
  • Leadership Quote: CEO Justin Hanka highlighted MindBio’s first‑mover advantage in AI‑powered voice diagnostics and expressed confidence in early industry engagement and upcoming deployments.

Notable Quotes

“MindBio is leveraging its first‑mover position in AI‑powered voice diagnostics to develop scalable workplace health and safety solutions addressing drug and alcohol impairment. We are encouraged by early industry engagement and look forward to initial deployment in Chile’s mining sector, followed by broader expansion across South America and other global markets.” – Justin Hanka, CEO

Read the original news release →

More from MindBio Therapeutics Corp.